Alembic Pharma gains on tentative approval for eye drops
Alembic Pharma gains on tentative approval for eye drops

Alembic Pharma gains on tentative approval for eye drops

Pratik Shastri Article rating: 5.0

Gujarat-based pharmaceutical company Alembic Pharma informed the bourses that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Bimatoprost Ophthalmic Solution.

Ten stocks close to their 52-weeks high
Ten stocks close to their 52-weeks high

Ten stocks close to their 52-weeks high

Shital Jibhe Article rating: 3.7

The markets on August 9, 2019 opened up. BSE Sensex is trading at 37,717.11, up by 389.75 points and the Nifty is trading at 11,158.85, up by 126.40 points. 

Nalco to form JV with Midhani for aluminium alloy plates
Nalco to form JV with Midhani for aluminium alloy plates

Nalco to form JV with Midhani for aluminium alloy plates

Pratik Shastri Article rating: 4.5

Government of India enterprise, Nalco, informed that it will create a JV with Mishra Dhatu Nigam for manufacturing of aluminium alloy plates and sheets, on Thursday after market hours.

Endurance Tech takes a U-turn
Endurance Tech takes a U-turn

Endurance Tech takes a U-turn

Gayathri Udyawar Article rating: 3.3

The auto components company withdrew plans to start the proposed tyre manufacturing business. Reacting to this development, the stock recovered more than 10 per cent from its 52-week low on Friday.

RSS
First22832284228522862288229022912292Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR